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non-IBD control patients. In CD patients membrane staining of ￿-catenin was generally weaker than in
control patients and more cells featured nuclear staining indicating transcriptionally active ￿-catenin, in
fibrotic areas. In these regions we also detected nuclear localisation of the transcription factor, SLUG,
which has also been implicated in EMT pathogenesis. Adjacent to the fibrotic tissue regions, we observed
high levels of FAP, a marker of reactive fibroblasts. CONCLUSIONS We demonstrate the presence of
EMT-associated molecules in fibrotic lesions of CD patients. These findings support the hypothesis that
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Abstract
Background: Intestinal fibrosis and subsequent stricture formation represent frequent complications of Crohn’s
disease (CD). In many organs, fibrosis develops as a result of epithelial to mesenchymal transition (EMT). Recent
studies suggested that EMT could be involved in intestinal fibrosis as a result of chronic inflammation. Here, we
investigated whether EMT might be involved in stricture formation in CD patients.
Methods: Human colonic tissue specimens from fibrotic areas of 18 CD and 10 non-IBD control patients were
studied. Immunohistochemical staining of CD68 (marker for monocytes/macrophages), transforming growth
factor-β1 (TGFβ1), β-catenin, SLUG, E-.cadherin, α-smooth muscle actin and fibroblast activation protein (FAP) were
performed using standard techniques.
Results: In fibrotic areas in the intestine of CD patients, a large number of CD68-positive mononuclear cells was
detectable suggesting an inflammatory character of the fibrosis. We found stronger expression of TGFβ1, the most
powerful driving force for EMT, in and around the fibrotic lesions of CD patients than in non-IBD control patients. In
CD patients membrane staining of β-catenin was generally weaker than in control patients and more cells featured
nuclear staining indicating transcriptionally active β-catenin, in fibrotic areas. In these regions we also detected
nuclear localisation of the transcription factor, SLUG, which has also been implicated in EMT pathogenesis. Adjacent
to the fibrotic tissue regions, we observed high levels of FAP, a marker of reactive fibroblasts.
Conclusions: We demonstrate the presence of EMT-associated molecules in fibrotic lesions of CD patients. These
findings support the hypothesis that EMT might play a role for the development of CD-associated intestinal fibrosis.
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Background
Though most of IBD patients initially present with an in-
flammatory pathology, due to the longstanding and chron-
ically relapsing disease, severe complications, such as
stenosis, strictures or fistulae occur [1]. With respect to
Crohn’s disease (CD), about 70% of patients suffer from
fistula and stenosis during their disease course and at least
60% require surgery at least once within 20 years following
their initial diagnosis [2]. About one third of CD patients
require surgery due to intestinal fibrosis or the resulting
complications, such as intestinal obstruction, during their
disease course. However, this often also does not provide
a definite solution and inflammation and restenosis fre-
quently re-occur [3]. Of note, there are distinct differences
between intestinal fibrosis in UC and CD patients: While
in UC, the colonic mucosa and sub-mucosa is affected, in
CD the fibrosis is transmural, mainly of the small and/or
large bowel, including submucosa, muscle layer and ser-
osa, but excluding the mucosa [4]. In contrast to CD, sur-
gery due to fibrotic complications is a rare event in UC
patients, whereas fibrotic events occur at least evenly. A
key problem with respect to inflammation-associated in-
testinal fibrosis is the fact that anti-inflammatory strat-
egies, such as anti-TNF antibodies or immunosuppressive
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medications, are not effective in preventing fibrosis and
that no specific anti-fibrotic medical therapy exists [4].
Current hypothesis suggests that the first step of intes-
tinal fibrosis is a tissue damage caused by a chronic in-
flammatory state. Subsequently, activated fibroblasts are
recruited to the sites of inflammation to induce wound
healing and, finally, fibrosis results due to excessive depos-
ition of extracellular matrix (ECM) [5,6]. Recently, is
has been demonstrated that miR-200b is involved in
intestinal fibrosis in CD patients [7]. Using an animal
model of chronic intestinal inflammation it was shown that
CD-associated intestinal fibrosis might be the result of
epithelial-to-mesenchymal transition (EMT) [8]. EMT is a
common process that plays a pivotal role for embryogen-
esis, organ development, tissue regeneration and wound
healing [9,10]. However, EMT is also involved in organ fi-
brosis as well as cancer progression and metastasis [9,11].
During EMT, epithelial cells lose their polarized phenotype
and convert into mesenchymal-like myofibroblasts which
is indicated by co-expression of epithelial markers, such as
E-cadherin or cytokeratines 8 and 20, and mesenchymal
markers, such as α-smooth muscle actin (α-SMA) or
vimentin, in EMT cells [10,12]. This way, EMT represents
one of the main sources of activated fibroblasts in many
organ systems and its most powerful mediator in vitro and
in vivo is transforming growth factor beta (TGFβ) [11-15].
Here, we demonstrate the presence of many EMT-related
proteins in fibrotic areas of intestinal tissue specimen derived
from CD patients. Our data suggest that EMT is essentially
involved in the pathogenesis of CD-associated intestinal
fibrosis. This finding might open the avenue for new and
more effective treatment options for intestinal fibrosis.
Methods
Patients
Colonic tissue specimens were obtained from fibrotic areas
of 18 CD patients (mean age 44 ± 4 years) or from the in-
testinal mucosa of 10 non-IBD control patients (mean age
62 ± 5 years). Intestinal samples were derived from male
and female patients (please see Additional file 1: Table S1
+ 2 for further details). Tissue specimens were collected
from endoscopic biopsies or surgical specimens from CD
patients or from non-IBD patients who underwent endos-
copy because of colon cancer screening, respectively.
Tissue specimens were immediately transferred into 4%
formalin and stored at 4°C until further analysis. Written
informed consent was obtained before specimen collection
and studies were approved by the Cantonal Ethics
Committee of the CAnton Zürich, Switzerland
Immunohistochemistry
We performed immunohistochemical studies on formalin-
fixed, paraffin-embedded tissue specimens using a per-
oxidase based method with diaminobenzidine (DAB)
chromogen as described previously [16]. Following in-
cubation of tissue samples with xylol and descending
concentrations of ethanol, antigens were retrieved using
citrate buffer, pH 6.0 (DAKO, Glostrup, Denmark) for
30 min at 98°C. Endogenous peroxidases were deleted
by incubation with 0.9% hydrogen peroxide for 15 min
at room temperature (RT) and blocking was performed
using 3% BSA for 1 h at RT. Antibodies were then
applied in an optimal concentration overnight in a wet
chamber. Rabbit anti-CD68 (Abcam, Cambridge, UK),
rabbit anti-β-catenin (Cell Signalling), rabbit anti-TGFβ
(Santa Cruz, Santa Cruz, CA), rabbit anti-SLUG (Abcam),
rabbit anti-E-cadherin (Cell Signalling, Danvers, MA),
rabbit anti-α-smooth muscle actin (SMA; Abcam) and
rabbit anti-fibroblast activating protein (FAP; Abcam) anti-
bodies were obtained from the sources noted. EnVision+
System-HRP-Labelled Polymer (DAKO) was used as a
secondary antibody and was applied for 1 h at RT. Anti-
body binding was visualized using Liquid DAB+ Substrate
Chromogen System (DAKO). Samples were counterstained
with hematoxylin, incubated in ascending concentrations
of ethanol and xylol solutions and finally mounted. For
microscopic assessment, an AxioCam MRc5 (Zeiss, Jena,
Germany) camera on a Zeiss Axiophot microscope (Zeiss)
wa used. Image analysis was performed using AxioVision
Release 4.7.2 software (Zeiss).
Results
Fibrotic lesions show CD68-positive mononuclear cells
Sites of severe inflammation often feature increased num-
bers of activated fibroblasts. These cells, also called myofi-
broblasts, play an important role for wound healing what
sometimes results in excessive production of ECM finally
leading to fibrosis. To identify fibrotic areas we visualized
collagen fibers using van Gieson staining, while we con-
firmed the presence of inflammatory cells in fibrotic areas
by CD68 staining, which is a well-established marker for
human monocytes and macrophages [17]. As expected,
we found a large number of CD68 positive cells in and
around fibrotic areas of colonic tissue samples from CD
patients (Figure 1), what correlates with the hypothesis
that intestinal fibrosis is associated with inflammation.
TGFβ is strongly expressed in fibrotic colonic CD tissue
TGFβ is widely regarded as the most powerful inducer
of EMT in vitro and in vivo. Since the most important
TGFβ isoform in humans is represented by TGFβ1, we
assessed expression of this particular molecule in our
study. First we investigated TGFβ1 expression in non-
IBD control patients without fibrosis. Here, the epithelial
layer showed a considerable staining intensity for TGFβ1,
while the staining in sub-mucosal layers was only
slightly detectable (Figures 2A + B). In contrast, in CD
patients with intestinal fibrosis, expression of TGFβ1 in
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the epithelial layer was stronger than in control patients
(Figure 2C). Further TGFβ1 expression in submucosal
layers and in particular in fibrotic areas was clearly more
in CD patients than in control patients (Figures 2D-F).
This difference could be observed in all of the tissue layers
from the lamina propria to the serosal layer.
Nuclear localisation of β-catenin in fibrotic areas
A well-established marker for the onset of EMT is nuclear
localisation of β-catenin. We first assessed β-catenin stain-
ing in the epithelial layer. In tissue samples from control
patients, all of the intestinal epithelial cells featured a
strong staining for β-catenin in the cell membrane while
the nuclei did not show any significant β-catenin staining.
In sub-mucosal layers almost no β-catenin was detectable
at all (Figures 3A + B). In CD patients membrane staining
of β-catenin was generally weaker than in control patients
and more cells featured nuclear staining indicating tran-
scriptionally active β-catenin (Figures 3C-F). In fibrotic
areas, nuclear expression of β-catenin was clearly higher
in fibroblasts than in control patients and fibrotic areas
featured hereby an even stronger nuclear staining intensity
for β-catenin (Figures 3C-F). The increased number of
cells featuring nuclear translocation of β-catenin was
also demonstrated by statistical analysis of nuclear β-
catenin positive cells per a well-defined field-of-view in
a representative subgroup of patients (Additional file 1:
Figure S1). These observations, loss of cell membrane-
bound β-catenin and increased nuclear localisation indica-
tive for transcriptionally active β-catenin in fibroblasts, are
Figure 1 CD68-positive mononuclear cells are present in fibrotic lesions. (A) Colonic tissue specimens from CD patients with active disease
feature a large amount of collagen fibers indicative for fibrosis as visualized by van-Gieson staining. (B) Same area as in (A) features strong
expression of CD68, a marker of activated monocytes/macrophages. (C) Fibrotic regions in the intestine of CD patients feature strong expression
of CD68. (D) Enlarged section from (C) featuring CD68-positive mononuclear cells. (E) Representative section from (C) visualizing collagen fibers
by van-Gieson staining. Magnification: 10-fold or 40-fold, respectively. All analysed patient samples showed comparable staining characteristics
when compared to samples from non-affected controls.
Scharl et al. Clinical and Translational Medicine  (2015) 4:1 Page 3 of 9
characteristic observations for EMT and further support
the observation that EMT might be involved in CD-
associated fibrosis.
SLUG transcription factor is upregulated in CD-associated
fibrosis
We next investigated the expression of Snail transcrip-
tion factor family members, namely SLUG and Snail1 in
fibrotic intestine of CD patients. We found strong SLUG
staining in fibroblast-like cells of fibrotic areas of colonic
tissue specimens derived from CD patients. Of notice,
SLUG was often visible in the nuclei of fibroblast-like
cells indicative for transcriptionally active SLUG protein
(Figure 4A-D). Increased expression and nuclear trans-
location of SLUG are often correlated with the onset of
EMT and our finding provides therefore a possible
mechanistic explanation how EMT-associated events in
fibrotic areas could be mediated on a transcriptional
level. Slug staining was almost completely absent in
non-IBD control patients (data not shown). Interestingly,
the transcription factor SNAIL1, was neither detectable
in non-IBD control patients nor in fibrotic regions of
CD patients (data not shown).
FAP is strongly expressed around areas of CD-associated
fibrosis
A number of studies indicated a role for FAP in the
pathogenesis of chronic inflammatory and fibrotic con-
ditions, such as liver cirrhosis. Since CD-associated fi-
brosis also occurs in response to chronic inflammation
of the intestinal wall, we investigated whether FAP, a
marker of fibroblast activation, would be expressed in
or around fibrotic areas in the intestine of CD patients.
Figure 5 demonstrates that FAP was only weakly
expressed in the fibrotic areas. However, we found a
strong, FAP-positive staining in fibroblasts adjacent to
the fibrotic areas.
Figure 2 Expression of TGFβ1 in fibrotic lesions. (A + B) In representative samples from two different non-IBD control patients, the epithelial
layer showed a considerable staining intensity for TGFβ1, while the staining in sub-mucosal layers was only slightly detectable. (C) In CD patients
with intestinal fibrosis, expression of TGFβ1 in the epithelial layer was strongly detectable. (D-F) In fibrotic areas, sub-mucosal TGF-β1 staining is
strongly detectable. Magnification: 20-fold or 40-fold, respectively. All analysed patient samples showed comparable staining characteristics when
compared to samples from non-affected controls.
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Expression of epithelial and mesenchymal markers in
fibrotic intestinal CD tissue
We next assessed the expression of E-cadherin which
is usually located in adherens junctions of epithelial
cell layers, connecting adjacent cells. We found strong
E-cadherin staining in the intestinal epithelial layer
(Figure 6A). However, we also detected expression of E-
cadherin in a number of subepithelial cells in and around
fibrotic areas (Figure 6B + C). Further, we found a large
number of α-SMA positive cells in fibrotic areas of intes-
tinal tissue specimens from CD patients (Figures 7A-B).
This co-incidence of mesenchymal and epithelial markers
in areas of fibrotic tissue strongly supports an involvement
of EMT in the pathogenesis of CD-associated fibrosis.
Discussion
CD-associated fibrosis and the resulting clinically rele-
vant stenosis and strictures represent a common and se-
vere complication in CD patients. To date, conventional
options for prevention or treatment of such fibrotic com-
plications are insufficient and even surgery is often only a
temporarily beneficial approach. The limitation in available
treatment options is mainly due to the fact that the patho-
genesis of CD-related fibrosis is only poorly understood.
Here, we demonstrate the presence of EMT-associated
events in fibrotic areas of colonic tissue specimens derived
from CD patients.
A characteristic feature of EMT is the translocation of
β-catenin from the cytosol, where it connects E-cadherin
to the actin cytoskeleton, into the nucleus to regulate gene
expression. During EMT, β-catenin translocates from the
cell membrane into the cytoplasm indicative for the disin-
tegration of the epithelial zonulae adherentes. Further, the
cytoplasmic pool of β-catenin translocates into the nu-
cleus and initiates the expression of EMT-associated
genes, such as α-SMA, vimentin or TGFβ [18,19]. TGFβ
has been shown to regulate expression and activity of
the Snail transcription factor family member, SLUG, via
β-catenin in epithelial cell systems and SLUG has also
been implicated in the pathogenesis of EMT via down-
regulation of E-cadherin [20]. Characteristically, acti-
vated fibroblasts express FAP and presence of FAP has
been implicated in the pathology of cancers, chronic in-
flammatory disorders, fibrosis and other pathologies
indicating possible roles for FAP in facilitating cell inva-
sion and growth [21].
Though EMT has already been associated with the
pathogenesis of fibrosis in many systems, such as kidney,
liver or lung [11], the evidence for EMT being involved in
the development of intestinal fibrosis in CD patients is
lacking. A recent study by Flier et al. identified EMT as a
source of fibroblasts in the TNBS model of inflammation-
associated intestinal fibrosis. They demonstrated that
intra-rectal administration of TNBS to mice induces in-
flammation and fibrosis that is histological and im-
munologically similar to human CD. The fibrotic areas
in these animals featured a large amount of cells ex-
pressing both, epithelial and mesenchymal markers, in-
dicative for the onset of EMT. In particular, fibrotic
areas revealed significantly more fibroblasts being α-
SMA-positive as well as being positive for both, the epi-
thelial cell marker E-cadherin and the fibroblast marker,
fibroblast-specific protein 1 (FSP1) [8]. However, the
observation period of these animals was certainly lim-
ited when compared to year-long duration of fibrogen-
esis in humans. Additionally, these mice did not develop
strictures that display one of the most severe complica-
tions of human intestinal fibrosis. In intestinal tissue
samples derived from three patients suffering from ei-
ther active UC or CD, they showed co-localisation of α-
SMA and E-cadherin in colonic crypts [8]. Nevertheless,
this patient number was certainly too small for demon-
strating finally conclusive results and the patients were
Figure 3 Expression of β-catenin in fibrotic lesions. (A + B) In
tissue samples from non-IBD control patients, the intestinal epithelial
cells featured a strong staining for β-catenin in the cell membrane
(black arrows) while the nuclei did not show any significant β-catenin
staining (white arrows). In sub-mucosal layers almost no β-catenin was
detectable (grey arrows). (C-F) In stenotic areas of CD patients clearly
more cells featured nuclear β-catenin staining (black arrows) indicating
transcriptionally active, meaning nuclear, β-catenin. Magnification:
10-fold, 40-fold or 100-fold, respectively. All analysed patient
samples showed comparable staining characteristics when compared
to samples from non-affected controls.
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also not featuring strictures as a complication of intes-
tinal fibrosis.
In our new animal model of intestinal fibrosis occur-
ring after heterotopic transplantation of small bowel re-
sections in rats we found rapid loss of crypt structures
which was followed by lymphocyte infiltration and obliter-
ation of the intestinal lumen by fibrous tissue. Loss of intes-
tinal epithelium was demonstrated by lack of cytokeratines
while collagen expression was increased with time after
transplantation. Interestingly, lumen obliteration was
Figure 4 The transcription factor SLUG is expressed in the nuclei of mesenchymal cells in fibrotic areas. (A-D) Representative images
demonstrate considerable SLUG staining in fibroblast-like cells of fibrotic areas of colonic tissue specimens derived from CD patients. SLUG is
visible in the nuclei of fibroblast-like cells (black arrows) indicative for transcriptionally active SLUG protein. The insert in (A) demonstrates
van-Gieson staining. Magnification: 10-fold or 40-fold, respectively. All analysed patient samples showed comparable staining characteristics when
compared to samples from non-affected controls.
Figure 5 FAP expression is strongly detectable in myofibroblasts adjacent to fibrotic areas. Representative images show (A) van-Gieson
staining and (B) corresponding FAP staining in fibrotic tissue samples derived from CD patients. (B-D) FAP staining is strongly detectable in
myofibroblasts adjacent to the fibrotic areas (black arrows), while FAP staining in myofibroblasts within fibrotic areas is limited (white arrows). Magnification:
10-fold. All analysed patient samples showed comparable staining characteristics when compared to samples from non-affected controls.
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connected with increased expression of factors associ-
ated with EMT such as β6 integrin, IL-13 and TGFβ.
The myofibroblast phenotype in fibrotic areas was demon-
strated by presence of the mesenchymal markers α-SMA
smooth muscle actin and vimentin in the obliterated
lumen. These observations demonstrate that a variety of
histologic and molecular features of fibrosis associated
EMT can be observed in the heterotopic intestinal grafts
[22]. Therefore, the data obtained in our new animal
model so far fully confirmed our data obtained in human
samples suggesting that the observations made in the ani-
mal model might actually reflect real fibrosis. This of par-
ticular interest, since it not only underlines the relevance
of our data presented in this manuscript, but also gives us
the possibility to perform further research using a repro-
ducible animal model. This might finally critically contrib-
ute to a better understanding of the complex pathogenesis
of intestinal fibrosis and the development and validation
of new therapeutic options.
Thus, the observations presented here are in good ac-
cordance with other findings from our laboratory, dem-
onstrating that EMT also is present in human CD and
contributes to the pathogenesis of CD-associated fistulae
[16,23-25]. Of note, intestinal fistulae are commonly
surrounded by areas featuring fibrotic lesions. However,
neither the findings in the animal models nor our previ-
ous data provided conclusive evidence that EMT might
be involved in the pathogenesis of intestinal fibrosis in
CD patients.
Here, we demonstrated that areas of intestinal fibrosis
in CD patients feature EMT-associated gene expression
events using colonic tissue specimens from fibrotic areas
of CD patients. We found significant staining of TGFβ
as well as of the EMT-associated transcription factor
SLUG in fibrotic areas. Additionally, we detected nuclear
localisation of β-catenin as a prominent feature of fi-
brotic regions. All of these molecules are associated with
the onset of EMT. In particular, in intestinal epithelial
Figure 6 Subepithelial cells in and around fibrotic areas express E-cadherin. Representative images show E-cadherin (A; C) and van-Gieson
(B) staining in corresponding tissue sections. Black arrows point onto E-cadherin positive cells. Magnification: 10-fold or 40-fold, respectively. All
analysed patient samples showed comparable staining characteristics when compared to samples from non-affected controls.
Figure 7 Subepithelial cells in and around fibrotic areas express α-SMA. Representative images show α-SMA (A) and van-Gieson (B) staining
in corresponding tissue sections. Magnification: 10-fold or 40-fold, respectively. All analysed patient samples showed comparable staining characteristics
when compared to samples from non-affected controls.
Scharl et al. Clinical and Translational Medicine  (2015) 4:1 Page 7 of 9
cells TGFβ can induce SLUG expression and activation
(meaning nuclear localisation) via β-catenin. Further,
activated SLUG as well as activated (meaning nuclear)
β-catenin play an important role for the downregulation
and disassembling of E-cadherin [12,15,18-20]. All of
these events (expression of TGFβ and nuclear localisa-
tion of SLUG and β-catenin) are characteristic for EMT
and were visible in human tissue samples featuring a
CD-associated fibrosis.
Of interest, FAP staining was strongly detectable in
fibroblasts adjacent to the fibrotic areas. Though FAP
expression is absent in most adult tissues, it is expressed
under chronic inflammatory and fibrotic conditions as
well as in certain epithelial tumours. On a functional
level, FAP features dipeptidyl- and endopeptidase activity
and seems to be involved in tumour cell proliferation
[21,26]. A recent study even suggested that FAP inhib-
ition might be beneficial for treating epithelial-derived
tumours, since pharmacologic targeting of FAP inhibited
tumour stromagenesis by affecting integrin-mediated sig-
nalling and led to a decreased recruitment and overall
number of myofibroblasts [27]. Therefore, one might
speculate, whether FAP could be a potential target for the
treatment of CD-associated intestinal fibrosis.
Conclusions
In summary, we have demonstrated the presence of
EMT-associated events in fibrotic areas in the colon of
CD patients. These findings suggest that EMT could play
a certain role for the pathogenesis of CD-associated in-
testinal fibrosis. Therefore our study might help to pro-
vide the rationale background for further investigations
unravelling the exact pathomechanisms of intestinal fi-
brosis what could finally help to develop more effective
therapeutic options for the treatment of CD-associated
intestinal fibrosis.
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